Prognostic and Predictive Factors in Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel and Estramustine: A Single Institution Experience-Reference-Cited by-同舟云学术

Prognostic and Predictive Factors in Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel and Estramustine: A Single Institution Experience

Published:2008-02 Issue:2 Volume:53 Page:323-332
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Bamias Aristotle,Bozas George,Antoniou Nikolaos,Poulias Iraklis,Katsifotis Harilaos,Skolarikos Andreas,Mitropoulos Dionysios,Alamanis Christos,Alivizatos Gerassimos,Deliveliotis Haralambos,Dimopoulos Meletios A.

Publisher

Elsevier BV

Subject

Urology

Reference34 articles.

1. Cancer statistics, 2006;Jemal;CA Cancer J Clin,2006

2. The current state of hormonal therapy for prostate cancer;Hellerstedt;CA Cancer J Clin,2002

3. Management of cancer of the prostate;Catalona;N Engl J Med,1994

4. Advances in prostate cancer chemotherapy: a new era begins;Pienta;CA Cancer J Clin,2005

5. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer;Yagoda;Cancer,1993

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial;BMC Cancer;2022-02-16

2. The efficacy and safety of abiraterone acetate in patients with high-risk prostate cancer: a meta-analysis based on six randomized control trials;Translational Andrology and Urology;2020-08

3. A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer;BMC Urology;2017-08-22

4. A systematic review of the impact of pain on overall survival in patients with cancer;Supportive Care in Cancer;2017-02-11

5. Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy;BMC Urology;2016-03-22